Bromocriptine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{Drugbox|
{{DrugProjectFormSinglePage
|IUPAC_name = Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2
|authorTag=
-methylpropyl)-
 
| image =
 
| CAS_number=25614-03-3
<!--Overview-->
| ATC_prefix=G02
 
| ATC_suffix=CB01
|genericName=
| ATC_supplemental={{ATC|N04|BC01}}
 
| PubChem=31101
 
| DrugBank=APRD00622
 
| C=32 | H=40 | Br=1 | N=5 | O=5
|aOrAn=
| molecular_weight = 654.595
 
| bioavailability= 28% of oral dose absorbed
a
| metabolism = ?
 
| elimination_half-life= 12-14 hours
|drugClass=
| excretion = 85% bile (faeces)
 
| pregnancy_category = A
 
| legal_status = ?
 
| routes_of_administration= oral
|indication=
}}
 
{{SI}}
 
{{CMG}}
 
|hasBlackBoxWarning=
 
Yes
 
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
*
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


==Overview==
<!--Brand Names-->
'''Bromocriptine''' (brand names include Parlodel), an [[ergoline]] derivative, is a [[dopamine agonist]] that is used in the treatment of [[pituitary]] [[tumors]] and [[Parkinson's disease]]. 


==Uses==
|brandNames=
[[Amenorrhea]], female [[infertility]], [[galactorrhea]], [[hypogonadism]], and [[acromegaly]] may all be caused by pituitary problems, such as [[hyperprolactinaemia]], and therefore, these problems may be treated by this drug.


It has also used in some countries to prevent lactation following childbirth if the mother does not wish to breastfeed; one of dopamine's effects on the pituitary is as an antagonist of [[prolactin]] production by [[lactotroph]]s. However, the FDA removed this indication in 1995, because of concerns with respect to an increased risk of heart attack, seizure and stroke.
* ®<ref>{{Cite web | title =  | url =  }}</ref>


Because of prolactin's role in stimulating proliferation of the [[T-lymphocyte]]s of the [[immune system]], bromocriptine has also been used to suppress the immune system in [[organ transplant]] patients.<ref>Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Muhlbacher F, Mustafa G, Horl WH, Waldhausl W, Mayer G, Luger A., 1997. [http://ndt.oxfordjournals.org/cgi/content/abstract/12/4/748 The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation]. Nephrol Dial Transplant. 1997 Apr;12(4):748-52.</ref>
<!--Look-Alike Drug Names-->


Since bromocryptine acts as a dopamine agonist, it has potential use in treating [[cocaine]] addiction, since the addictive effects of cocaine are caused by it blocking dopamine [[reuptake]]. Although it has negligible subjective effects when administered alone, studies show it has the potential to significantly ease the cocaine [[withdrawal]] syndrome.<ref>Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh E, Kula NS, 1989. Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 1989 Sep; 2(3):209-24.</ref><ref>KL Preston, JT Sullivan, EC Strain and GE Bigelow, 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther. 1992 Jul;262(1):279-91.</ref>
|lookAlike=


There appear to be some connections between [[insulin insensitivity]] and [[dopamine]]. A company called Veroscience <ref>http://www.veroscience.com/research.html</ref> is using bromocriptine to treat [[diabetes]] and [[obesity]], and their website postulates a connection between neurotransmitters and seasonal variation in [[insulin]] sensitivity among vetebrate animals.<ref>Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707.</ref> There are also some connections between temperature and dopamine and serotonin production.<ref>http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_281.html</ref> In addition, new research indicates that patients with [[diabetes]] are more likely to develop [[parkinson's disease]], which is characterized by a dopamine deficiency in the brain.
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


===Pill Images===
<!--Drug Shortage Status-->
{{TempDrugImages}}
{{PillImage|fileName=Parlodel_NDC_00780017.jpg|drugName=Parlodel|NDC=00780017|drugAuthor=Novartis Pharmaceuticals Corporation|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=PARLODEL;2;12|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=8|pillScore=2}}
{{PillImage|fileName=Parlodel_NDC_00780102.jpg|drugName=Parlodel|NDC=00780102|drugAuthor=Novartis Pharmaceuticals Corporation|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=PARLODEL;5;mg;S|dosageValue=5|dosageUnit=mg|pillColor=Brown|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=Bromocriptine_Mesylate_NDC_03782042.jpg|drugName=Bromocriptine Mesylate|NDC=03782042|drugAuthor=Mylan Pharmaceuticals Inc.|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=M;42|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=7|pillScore=2}}
{{PillImage|fileName=Bromocriptine_Mesylate_NDC_03787096.jpg|drugName=Bromocriptine Mesylate|NDC=03787096|drugAuthor=Mylan Pharmaceuticals Inc.|ingredients=BROMOCRIPTINE MESYLATE[BROMOCRIPTINE]|pillImprint=MYLAN;7096|dosageValue=5|dosageUnit=mg|pillColor=Brown;White|pillShape=Capsule|pillSize=14|pillScore=1}}
{{PillImage|fileName=Bromocriptine_mesylate_NDC_05740106.jpg|drugName=Bromocriptine mesylate|NDC=05740106|drugAuthor=Paddock Laboratories, Inc.|ingredients=Bromocriptine mesylate[Bromocriptine]|pillImprint=PAD;0106|dosageValue=2.5|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=8|pillScore=2}}
{{PillImage|fileName=CYCLOSET_NDC_680120258.jpg|drugName=CYCLOSET|NDC=680120258|drugAuthor=Santarus, Inc.|ingredients=bromocriptine mesylate[bromocriptine]|pillImprint=C;9|dosageValue=0.8|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=6|pillScore=1}}


|drugShortage=
}}


==Structure==
<!--Pill Image-->
Like all [[ergoline|ergopeptides]], bromocriptine is a [[cyclol]]; two peptide groups of its tri[[peptide]] moiety (shown in black at the upper left of the Figure) are crosslinked, forming the >N-C(OH)< juncture between the two [[lactam]] rings.


==See also==
{{PillImage
[[Cabergoline]]
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


<!--Label Display Image-->


==References==
{{LabelImage
{{reflist|2}}
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{Ergolines}}
<!--Category-->
{{Dopamine agonists}}
[[Category:Dopamine agonists]]
[[Category:Drugs]]


[[de:Bromocriptin]]
[[Category:Drug]]
[[es:Bromocriptina]]
[[hu:Bromokriptin]]
[[it:Bromocriptina]]
[[ru:Бромокриптин]]
[[sv:Bromokriptin]]
{{WikiDoc Help Menu}}

Revision as of 21:10, 7 January 2015

Bromocriptine
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Bromocriptine is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Bromocriptine in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bromocriptine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Bromocriptine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Bromocriptine in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Bromocriptine in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Bromocriptine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Bromocriptine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Bromocriptine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Bromocriptine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Bromocriptine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Bromocriptine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Bromocriptine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Bromocriptine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Bromocriptine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Bromocriptine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Bromocriptine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Bromocriptine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Bromocriptine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Bromocriptine in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Bromocriptine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Bromocriptine in the drug label.

Pharmacology

There is limited information regarding Bromocriptine Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Bromocriptine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Bromocriptine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Bromocriptine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Bromocriptine in the drug label.

How Supplied

Storage

There is limited information regarding Bromocriptine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Bromocriptine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Bromocriptine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Bromocriptine in the drug label.

Precautions with Alcohol

  • Alcohol-Bromocriptine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Bromocriptine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Bromocriptine
 |Label Name=Bromocriptine11.png

}}


{{#subobject: 

 |Label Page=Bromocriptine
 |Label Name=Bromocriptine11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Bromocriptine&oldid=1052579"